Avapag 20 mg is a drug that contains Avatrombopag, a thrombopoietin receptor agonist( TPO- RA) used primarily to treat thrombocytopenia( a bleeding complaint characterized by an abnormally low platelet count) in some medical conditions. Avatrombopag is an oral, small- patch agent that stimulates platelet product via the activation of the thrombopoietin receptor, making the platelet count of cases safe for procedures or farther treatment.

Avapag tablets 20 mg each have 20 milligrams of Avatrombopag maleate fellow to 20 mg of Avatrombopag free base. The tablets are film- carpeted and taken orally formerly daily as specified by a health care provider. The expression is designed to have steady immersion and predictable pharmacokinetics anyhow of whether it's with or without food.

Avatrombopag is an agonist of the thrombopoietin receptor( TPO- R, c- Mpl) on bone gist hematopoietic cells. It mimics the action of endogenous thrombopoietin, a hormone that naturally regulates the product of platelets. Through binding and activation of this receptor, Avapag promotes proliferation and isolation of megakaryocytes — the bone gist cells responsible for platelet product — performing in increased counts of platelets in the blood.

Avapag 20 mg is used in the treatment of two main conditions

Thrombocytopenia in Grown-ups with habitual Liver complaint( CLD)

Avapag is used for the increase of platelet counts in adult cases with habitual liver complaint who are witnessing a medical or dental procedure. It's common for CLD cases to have low platelet counts, and there's a lesser threat of bleeding with invasive procedures. Avatrombopag operates by neutralizing this threat by briefly elevating platelet counts.

habitual Immune Thrombocytopenia( ITP)

In adult cases with habitual vulnerable thrombocytopenia who have n't responded adequately to former treatment( e.g., corticosteroids or immunoglobulins), Avapag offers a long- term volition for adding and maintaining safe platelet counts.

The lozenge schedule of Avapag 20 mg varies according to the suggestion

For CLD cases previous to procedure The usual course of treatment is 5 days, generally started 10 – 13 days prior to the listed procedure, depending on the original platelet count. There are no salutary restrictions.

For ITP cases Treatment is generally initiated at 20 mg formerly daily and acclimated grounded on the case's platelet count response. Close monitoring of platelet counts during regular visits to the office maximizes the cure and minimizes the threat for thrombosis.

Avapag should be taken at the same time daily and should be swallowed whole with water.

Oral Convenience Unlike platelet transfusions or injectable specifics, Avapag offers an oral tablet lozenge form accessibly.

Predictable Response Avatrombopag has been seen in clinical studies to safely and predictably raise platelet counts.

No Dietary Restrictions Avapag can be taken with or without food, which is accessible for the case.

The most frequent side effects of Avapag 20 mg are

Headache

Fatigue

Nausea

Fever

Abdominal pain

Infrequently, more serious side goods may do, similar as

Thromboembolic complications( blood clots)

Liver function abnormalities

Acuity responses

The case should consult a croaker incontinently if the symptoms of blood clots( lump of the leg, pain in the casket, or difficulty breathing) are endured.

Thrombosis threat Avatrombopag may increase the threat of blood clots, especially in cases with underpinning threat factors. Cure adaptation and close monitoring are needed.

Hepatic Impairment Although Avapag is frequently used in cases with liver complaint, dosing should be personalized and liver function should be covered.

Gestation and Breastfeeding The safety of Avatrombopag in gestation or breastfeeding has not been well studied. Use only if easily necessary and under medical supervision.

Medicine relations Avatrombopag is broken down in the body by the liver enzymes CYP2C9 and CYP3A. Co-administration of its impediments or corrupters should be with caution.

Avapag 20 mg should be stored in a cool dry place below 30 °C( 86 °F), down from direct sun and humidity. Keep out of reach of children.

Avapag 20 mg is a advance in the treatment of thrombocytopenia in the form of anon-invasive, effective, and accessible remedy that increases platelet counts. Its binary suggestion for vulnerable thrombocytopenia and habitual liver complaint- associated makes it a precious medicine in hematologic remedy. As with any medicine, it should be used under the guidance of a medical professional to insure safety and get the stylish results.